Veracyte stock: Veracyte presents 401-patient Decipher evidence for Veracyte stock

Published on 10/24/2026 at 00:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Decipher covered 401 patients and 27,000 real-world cases. Veracyte stock has November 4 results scheduled and Q2 revenue of USD 150.3 million.

Evidence and reporting date

Veracyte's Decipher analysis covered 401 patients on October 23, 2026.
Second-quarter 2026 revenue reached USD 150.3 million, up 15.5 percent year over year.
Veracyte will discuss third-quarter 2026 results on November 4, 2026.

VCYT, US92337F1075, Illustration mit AI erstellt.

Veracyte (ISIN US92337F1075) presented evidence from a 401-patient phase III STAMPEDE analysis showing that its Decipher test can identify patients more likely to benefit from abiraterone. Zonebourse reported the new findings on October 23, 2026.

What does the evidence add?

The analysis found that the absolute five-year reduction in distant-metastasis events was 10 percent for patients with high Decipher scores and 11 percent for those with very high scores, compared with 2 percent for patients with lower scores. The study therefore supplied a quantified treatment-selection signal rather than only a risk classification.

Three dated company developments

On September 14, 2026, Veracyte acquired Convergent Genomics for USD 180 million, according to Zonebourse. On October 19, 2026, Veracyte announced six studies involving its genomic tests at the European Society for Medical Oncology congress, including new Decipher evidence, as detailed in the company's Veracyte release. The October 23, 2026, STAMPEDE analysis involved 401 patients.

Revenue gives the evidence context

Veracyte generated USD 150.32 million in second-quarter 2026 revenue, 15.5 percent more than in the year-earlier quarter. Adjusted earnings per share reached USD 0.54 against a USD 0.41 consensus estimate, while the company also raised its full-year 2026 revenue outlook to USD 590 million to USD 596 million, according to Zonebourse.

Dates for the next results

Veracyte's ESMO presentations include an October 24, 2026, oral session on Decipher treatment-selection evidence, according to Veracyte. The next reporting date is November 4, 2026, when the company is scheduled to discuss third-quarter results at 4:30 p.m. ET, according to its investor-relations page.

Market context and company profile

VCYT was last quoted at USD 47.93 on Nasdaq on October 23, 2026, at 4:00 p.m. ET in after-hours trading. The finance snapshot showed a market capitalization of USD 3.9 billion and a 52-week range of USD 29.45 to USD 60.91. Veracyte develops genomic diagnostic tests for thyroid, prostate, breast, bladder and lung cancers.

The further course of trading is shown by the continuously updated real-time quote of Veracyte stock.